BD Physioject allows self-injection of drugs for chronic diseases

Published: 7-Feb-2012
Medical Devices Pharmaceutical

Disposable device offers one-button activation and needle protection after injection

The BD Physioject disposable auto-injector from BD Medical, a division of Becton, Dickinson and Company (BD), is for self-injection of drugs for chronic diseases such as rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis.

The auto-injector offers easy, one-button activation, 360° view of the drug and injection process, visual confirmation of the end of injection, and protection of the needle after injection.

BD Physioject can be customised to offer a modified external design, flexible injection duration, a range of possible subcutaneous injection depths, and various syringe options (such as an end-of-dose indicator). It also includes a straightforward two-part assembly process that simplifies production and manufacturing.

The device is used in combination with the BD Hypak for Biotech syringe, a primary container for biologics, to provide a low level of interaction with such drugs.

Merck Serono uses Physioject as the platform for RebiDose, the Rebif pre-filled pen, for the treatment of multiple sclerosis. RebiDose was approved in Europe and Australia in October 2010.

  • Companies:
  • Becton Dickinson
See more

You may also like

Design & Build

BD to invest $100 million in Nebraska to expand insulin syringe manufacturing

Read more
Investment will include new technology and manufacturing equipment

Trending Articles

  1. Johnson & Johnson completes V-Wave acquisition to support patients with heart failure The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease
  2. Roche's breast cancer combination therapy Itovebi bags FDA approval Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
  3. Thermo Fisher scientific launches iCAP MX series ICP-MS for trace elemental analysis New platform simplifies analysis while enhancing productivity and accuracy
  4. Mosaic Therapeutics appoints Dr Barry Davies as its CSO Barry will bring more than 25 years of experience in drug development and lead optimisation to the table
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

You may also like

Design & Build

BD to invest $100 million in Nebraska to expand insulin syringe manufacturing

Investment will include new technology and manufacturing equipment
Drug Delivery

Aptar Pharma announces development and license agreement with BD to bring a novel autoinjector to market

AptarGroup is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer healthcare, injectables, food and beverage markets
Drug Delivery

BD expands portfolio with Sterifill Advance prefillable syringe

Offers reduced breakage and glass-like transparency
Packaging

BD pen needle innovation makes injections easier

US firm BD adds EasyFlow technology to BD Ultra-Fine Nano 4mm pen needles for diabetes injections
Packaging

BD launches BD Neopak prefillable syringe system

For biopharmaceutical injectable drug delivery
Medical Devices

BD expands into prefilled injectable generic products

First drug in BD Simplist family of products approved by US FDA
Drug Delivery

BD to buy Safety Syringes

BD to offer a drug delivery system with a safety guard that automatically locks into place
Subscribe now